No headlines found.
Globe Newswire (Mon, 9-Mar 8:30 AM ET)
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Thu, 19-Feb 8:30 AM ET)
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Globe Newswire (Wed, 11-Feb 6:30 AM ET)
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Globe Newswire (Wed, 4-Feb 8:30 AM ET)
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Veru trades on the NASDAQ stock market under the symbol VERU.
As of March 24, 2026, VERU stock price declined to $2.29 with 22,892 million shares trading.
VERU has a beta of 0.07, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.00 to the broad based SPY ETF.
VERU has a market cap of $36.76 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, VERU traded as high as $19.20 and as low as $2.10.
The top ETF exchange traded funds that VERU belongs to (by Net Assets): VTI, VXF.
VERU has underperformed the market in the last year with a price return of -55.7% while the SPY ETF gained +17.1%. However, in the short term, VERU had mixed performance relative to the market. It has outperformed in the last 3 months, returning -1.3% vs -4.8% return in SPY. But in the last 2 weeks, VERU shares have been beat by the market, returning -6.9% compared to an SPY return of -3.4%.
VERU support price is $2.20 and resistance is $2.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.